Plasma Cell Pete (@plasmacellpete) 's Twitter Profile
Plasma Cell Pete

@plasmacellpete

ID: 1162575205622878208

calendar_today17-08-2019 04:02:04

34 Tweet

545 Followers

49 Following

Plasma Cell Pete (@plasmacellpete) 's Twitter Profile Photo

On October 21 and 22, Levine Cancer Institute will be hosting its 2nd Annual Charlotte Hematologic Malignancies Congress. We have an all-star KOL cast presenting / debating the latest data! Join us face to face or virtually for this incredible opportunity! charlotteahec.org/event/68339

Plasma Cell Pete (@plasmacellpete) 's Twitter Profile Photo

LCI’s 2nd Annual Heme Malignancies Congress is fast approaching on 10/21 and 10/22! The F2F event is fully registered but we encourage virtual participation, too! Register now and get up-to-date with the latest updates in blood cancers from world experts! charlotteahec.org/event/68339

Plasma Cell Pete (@plasmacellpete) 's Twitter Profile Photo

Not too late to join the Levine Cancer Institute’s 2nd Annual Charlotte Hematologic Malignancies Congress virtually on 10/21 and 10/22! Terrific lineup of speakers! Register at charlotteahec.org/event/68339

Plasma Cell Pete (@plasmacellpete) 's Twitter Profile Photo

Talquetamab, a first-in-class GPRC5D -targeted bispecific antibody, has been approved by the FDA. This is a major step forward for the multiple myeloma field and a huge win for patients with relapsed / refractory disease!!!

Plasma Cell Pete (@plasmacellpete) 's Twitter Profile Photo

The Levine Cancer Institute Myeloma Team with Shebli Atrash and Plasma Cell Pete leading the charge, running for the cure at the Charlotte MMRF run on Sept. 16!

The Levine Cancer Institute Myeloma Team with Shebli Atrash and Plasma Cell Pete leading the charge, running for the cure at the Charlotte MMRF run on Sept. 16!
Plasma Cell Pete (@plasmacellpete) 's Twitter Profile Photo

Levine Cancer Institute partnering with the MMRF to cure myeloma. Thanks to the MMRF team for their support of our patients! We are getting closer!!! ⁦Shebli Atrash⁩ ⁦Levine Cancer⁩ ⁦Atrium Health⁩ ⁦Multiple Myeloma RF

Levine Cancer Institute partnering with the MMRF to cure myeloma.  Thanks to the MMRF team for their support of our patients! We are getting closer!!! ⁦<a href="/AtrashShebli/">Shebli Atrash</a>⁩ ⁦<a href="/LevineCancer/">Levine Cancer</a>⁩ ⁦<a href="/AtriumHealth/">Atrium Health</a>⁩ ⁦<a href="/theMMRF/">Multiple Myeloma RF</a>⁩
Plasma Cell Pete (@plasmacellpete) 's Twitter Profile Photo

The Charlotte HealthTree Myeloma Roundtable is 3 days away!!! Patients and loved ones, we look forward to seeing you for a great day of myeloma learning! healthtree.org/myeloma/commun…

Plasma Cell Pete (@plasmacellpete) 's Twitter Profile Photo

Achievement of MRD negativity 1 year after transplant is associated with improved progression-free and overall survival. Congrats to Dr. Pasquini and the BMT CTN 0702 / STaMINA investigators! pubmed.ncbi.nlm.nih.gov/38701390/

Plasma Cell Pete (@plasmacellpete) 's Twitter Profile Photo

Join me and my dear colleagues Saad Usmani and Noopur Raje as we discuss the rapidly changing landscape of newly diagnosed myeloma. We welcome you to join us at this PER satellite symposium Sunday night , Hilton Chicago, at the annual ASCO meeting! event.gotoper.com/event/e047acf4…

@MyelomaTeacher - Cindy Chmielewski (@myelomateacher) 's Twitter Profile Photo

When #ASCO24 tells you that non-profits are not allowed to bring a media team to the conference you go to #EHA24 to record myeloma news video instead! Headed to Madrid early to do some sightseeing before the conference. Who else will be there? #mmsm

When #ASCO24 tells you that non-profits are not allowed to bring a media team to the conference you go to #EHA24 to record myeloma news video instead! Headed to Madrid early to do some sightseeing before the conference. Who else will be there?  #mmsm
AbbVie Oncology Medical Affairs (@abbvieusoncmed) 's Twitter Profile Photo

NEWS: We are excited to announce that the first patient has been dosed in the Phase 3 study evaluating an investigational BCMA-directed bispecific antibody for patients with relapsed/refractory #MultipleMyeloma. Read more: bit.ly/3yVYkBG. Plasma Cell Pete #mmsm

NEWS: We are excited to announce that the first patient has been dosed in the Phase 3 study evaluating an investigational BCMA-directed bispecific antibody for patients with relapsed/refractory #MultipleMyeloma. Read more: bit.ly/3yVYkBG. <a href="/PlasmaCellPete/">Plasma Cell Pete</a> #mmsm
Plasma Cell Pete (@plasmacellpete) 's Twitter Profile Photo

Patients with myeloma and loved ones, please join us on June 22nd in Charlotte for a terrific International Myeloma Foundation Regional Community Workshop! myeloma.org/events/imf-per…(IMF,2024%2C%20in%20Charlotte%2C%20NC.